Research Interests for Daniel B. Mark

Dr. Mark is a Professor of Medicine at the Duke University Medical Center and is the Director of the Outcomes Research and Assessment Group in the Duke Clinical Research Institute.  The Outcomes group consists of 60 faculty and staff including physicians, economists, statisticians, and health policy researchers.  
Dr. Mark's major research interests include medical economics and quality of life outcomes, outcomes research, and quality of medical care.  Recent research projects directed by Dr. Mark include a 4,000-patient multi-dimensional technology assessment of coronary angioplasty (AHCPR); a 3,000-patient study of psychosocial prognostic factors in coronary disease (NHLBI); economic substudies in the ESSENCE (low molecular weight heparin in acute ischemic syndromes), EPISTENT (abciximab versus stents for percutaneous revascularization), and PURSUIT (eptifibatide in acute coronary syndrome patients) multi-center randomized trials; and a 3,000-patient substudy of economics and quality of life in the GUSTO megatrial (streptokinase versus t-PA). The latter investigation led to a cost-effectiveness analysis of t-PA and an international comparison of resource use and quality of life outcomes in Canadian and US patients in the year following myocardial infarction (both published in The New England Journal of Medicine).  
Currently, Dr. Mark is directing a number of cost-effectiveness analyses for ongoing clinical trials including OAT (percutaneous revascularization versus medical therapy for occluded infarct arteries, NIH), STICH (surgical treatment for ischemic heart failure, NIH), and ADEPT (rate adaptive pacemaker therapy, NIH).  He is the principal author of the AHCPR Unstable Angina Guidelines and a co-author of both the American College of Cardiology Guideline on Exercise Testing and their Coronary Stent Consensus Guideline.  He is also the Editor of the American Heart Journal.  Dr. Mark has published over 150 peer-reviewed articles, two books, and over 60 book chapters.  He lectures widely in the US, as well as in Canada, South America, and Europe.
Keywords: cost-effectiveness analysis, disease management, quality of life assessment, resource use.

Representative Publications

1. Mark DB, Harrington RA, Lincoff AM, Califf RM, Nelson CL, Tsiatis AA, Buell HE, Mahaffey KW, Davidson-Ray L, Topol EJ. Cost effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with Non-ST elevation acute coronary syndromes. Circulation 2000;101(4):366-371.
2. Braunwald E, Mark DB, Jones RH, Cheitlin MD, Fuster V, McCauley KM, Edwards C, Green LA, Mushlin AI, Swain JA, Smith EE, Cowan M, Rose GC, Concannon CA, Grines CL, Brown L, Lytle BW, Goldman L, Topol EJ, Willerson JT, Brown J, Archibald N. Diagnosing and managing unstable angina. Clinical Practice Guideline Number X. AHCPR Publication No. 97-N010. December 1996.
3. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong P, Barbash G, White H, Simoons ML, Nelson CL, Clapp-Channing N, Knight JD, Harrell FE Jr., Simes J, Topol EJ. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332(21):1418-1424.
4. Mark DB, Naylor CD, Hlatky MA, Califf RM, Topol EJ, Granger CB, Knight JD, Nelson CL, Lee KL, Clapp-Channing N, Sutherland W, Pilote L, Armstrong PW. Use of medical resources and quality of life outcomes after acute myocardial infarction in Canada versus the United States. N Engl J Med 1994;331(17):1130-1135.
5. Mark DB, Shaw L, Harrell FE Jr., Hlatky MA, Lee KL, Bengtson JR, McCants CB, Califf RM, Pryor DB. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med 1991;325:849-53.